Author:
Centore Richard C.,Soares Luis M. M.,Topal Salih,Vaswani Rishi G.,Ichikawa Kana,Li Zhifang,Fan Hong,Setser Jeremy W.,Lahr David L.,Zawadzke Laura E.,Chen Xueying,Barnash Kimberly D.,Muwanguzi Jordana,Anthony Neville,Sandoval Gabriel J.,Feldman Katharine,Elliott GiNell,Adam Ammar,Huang David,Davenport Yunji,Schiller Shawn,Wilson Kevin J.,Voigt Johannes,Xu Lan,Hentemann Martin,Millan David S.,Chan Ho Man,Decicco Carl P.,Kruger Ryan G.,Bellon Steven F.
Abstract
AbstractThe BRG/Brahma-associated factors (BAF or mSWI/SNF) family of chromatin remodeling complexes are critical regulators of gene expression and are major determinants of cancer and other diseases. Two paralog ATPases, SMARCA4 and SMARCA2 (BRG1 and BRM, respectively), provide the enzymatic activity required for chromatin remodeling. Here, we discover and characterize a novel series of compounds that potently and selectively inhibit SMARCA4/SMARCA2. Mutational and biochemical studies demonstrate that these inhibitors act through a unique mode of inhibition, distinct from reported SMARCA4/SMARCA2 inhibitors. Across a range of cancer cell lines, SMARCA4/SMARCA2 inhibition resulted in lineage-specific changes in chromatin accessibility at binding sites for key transcription factors (TFs). In uveal melanoma (UM), BAF inhibition resulted in loss of enhancer occupancy of SOX10 and MITF, two essential TFs, leading to down-regulation of the melanocytic gene expression program. In a mouse xenograft model of UM, SMARCA4/SMARCA2 inhibition was well tolerated and resulted in dose-dependent tumor regression correlating with pharmacodynamic modulation of BAF-target gene expression. These data provide the foundation for first-in-human studies of BAF ATPase inhibition as a novel therapeutic to treat TF-dependent cancers.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献